^
HER-2 overexpression
Hormone Receptor Negative Breast Cancer
trastuzumab + lapatinib
Sensitive: A1 - Approval
HR negative
Hormone Receptor Negative Breast Cancer
TCHP
Sensitive: C3 – Early Trials
HER-2 amplification + HER-2 R157W
Hormone Receptor Negative Breast Cancer
pyrotinib
Sensitive: C4 – Case Studies